- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04005755
Maxigesic® IV Phase 3 Exposure Study
A Phase 3, Open-Label, Multiple-Dose, Single-Arm Exposure Study of Maxigesic® IV in Patients With Acute Pain Following Orthopedic, General or Plastic Surgery
Study Overview
Detailed Description
Combined administration of acetaminophen and ibuprofen has been shown to provide superior analgesia over administration of comparable doses of either component alone or placebo, when given as an intravenous formulation or as a solid oral tablet in the postoperative setting.
The superior efficacy of the combination does not appear to come at the expense of tolerability. A previous study of Maxigesic® IV in bunionectomy patients found that there were no differences between patients treated with repeated doses of Maxigesic® IV and those treated with intravenous acetaminophen, ibuprofen or placebo in the rate of discontinuations due to adverse events (AEs), the overall incidence of treatment-emergent AEs (TEAEs) or the severity of TEAEs. The incidence of common TEAEs (affecting ≥ 10% of the study population), including gastrointestinal disorders, nervous system disorders, general disorders and administration site conditions, and skin and subcutaneous tissue disorders, was not changed due to combined administration of acetaminophen and ibuprofen in Maxigesic® IV.
This study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure (≥ 48 hours).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Christchurch, New Zealand
- Southern Clinical Trials
-
Christchurch, New Zealand, 8083
- Canterbury Geriatric Medical Research Trust
-
-
-
-
Maryland
-
Pasadena, Maryland, United States, 21122
- Chesapeake Reserach Group
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Chapel Hill Research Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is male or female ≥ 18 years of age.
- Is classified by the anesthesiologist as P1 to P2 in the American Society of Anesthesiologists (ASA) Physical Status Classification System.
- Requires multiple doses of parenterally administered nonopioid analgesics over multiple days as a result of surgery (non-laparoscopic general, plastic or orthopedic surgery).
- Has an expected stay in facility ≥ 48 hours.
- Has a body weight ≥ 45 kg.
- If female and of childbearing potential, is nonlactating and nonpregnant.
- If female, is either not of childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy, or hysterectomy]) or practicing 1 of the following medically acceptable methods of birth control: i) Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject's usual menstrual cycle period) before study drug administration; ii) Total abstinence from sexual intercourse since the last menses before study drug administration through completion of final study visit; iii) Intrauterine device (IUD); iv) Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream).
- Is able to provide written informed consent to participate in the study and able to understand the procedures and study requirements.
- Must voluntarily sign and date an informed consent form (ICF) that is approved by an Institutional Review Board (IRB) before the conduct of any study procedure.
- Is willing and able to remain at the study site for at least 48 hours and to attend a follow-up visit at 7 ± 2 days after the last dose of study drug.
Exclusion Criteria:
- Has a known history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, opioids, or any nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen); history of NSAID-induced bronchospasm (subjects with the triad of asthma, nasal polyps, and chronic rhinitis are at greater risk for bronchospasm and should be considered carefully); or hypersensitivity, allergy, or significant reaction to sulfa (including sulfonamide) medicines, ingredients of the study drug, or any other drugs used in the study including anesthetics and antibiotics that may be required on the day of surgery.
- Has experienced any surgical complications or other issues that, in the opinion of the Investigator, could compromise the safety of the subject if he or she participates in the study or could confound the results of the study.
- Has a known or suspected history of alcoholism or drug abuse or misuse within 2 years of screening or evidence of tolerance or physical dependence before dosing with study drug.
- Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease or any other condition that, in the opinion of the Investigator, could compromise the subject's welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.
- Has a history or current diagnosis of a significant psychiatric disorder that, in the opinion of the Investigator, would affect the subject's ability to comply with the study requirements.
- Has tested positive either on the urine drug screen or on the alcohol breathalyzer test. Subjects who test positive and can produce a prescription for the medication from their physician may be considered for study enrolment at the discretion of the Investigator.
- Has a history of a clinically significant (Investigator opinion) gastrointestinal (GI) event within 6 months before screening or has any history of peptic or gastric ulcers or GI bleeding.
- Has a surgical or medical condition of the GI or renal system that might significantly alter the absorption, distribution, or excretion of any drug substance.
- Is considered by the Investigator, for any reason to be an unsuitable candidate to receive the study drug.
- Is receiving systemic chemotherapy, has an active malignancy of any type, or has been diagnosed with cancer within 5 years before Screening (excluding treated squamous or basal cell carcinoma of the skin).
- Is currently receiving anticoagulants (e.g. heparin or warfarin).
- Has received a course of systemic corticosteroids (either oral or parenteral) within 3 months before screening (inhaled nasal steroids and regional/limited area application of topical corticosteroids (Investigator discretion) are allowed).
- Has a history of chronic use (defined as daily use for > 2 weeks) of NSAIDs, opiates, or glucocorticoids (except inhaled nasal steroids and regional/limited topical corticosteroids), for any condition within 6 months before study drug administration. Aspirin at a daily dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the subject has been on a stable dose regimen for ≥ 30 days before screening and has not experienced any relevant medical problem.
- Has a significant renal or hepatic disease, as indicated by clinical laboratory assessment (results ≥ 3 times the upper limit of normal [ULN] for any liver function test, including aspartate aminotransferase [AST], alanine aminotransferase [ALT], or creatinine ≥ 1.5 times the ULN).
- Has any clinically significant laboratory finding at screening that, in the opinion of the Investigator, contraindicates study participation.
- Previously participated in another clinical study of Maxigesic® IV or received any investigational drug or device or investigational therapy within 30 days before Screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Maxigesic® IV
Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion.
The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes.
The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
|
acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of TEAEs (Treatment-emergent Adverse Events)
Time Frame: During treatment period (≥ 48 hours - 5 days)
|
The incidence of treatment-emergent adverse events associated with exposure Maxigesic® IV
|
During treatment period (≥ 48 hours - 5 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time Course of TEAEs
Time Frame: After receiving the first dose of study medication until 7 days after the last dose, a total of approximately 9 days for subjects who received the treatment for 48 hours and 12 days for subjects who received the treatment for 5 days.
|
The incidence of treatment-emergent adverse events associated with exposure Maxigesic® IV during various study time periods
|
After receiving the first dose of study medication until 7 days after the last dose, a total of approximately 9 days for subjects who received the treatment for 48 hours and 12 days for subjects who received the treatment for 5 days.
|
Incidence of TRAEs (Treatment-related Adverse Events)
Time Frame: During treatment period (≥ 48 hours - 5 days)
|
The incidence of treatment-related adverse events (TEAEs considered by the investigator to be "probably" or "definitely" related to the study drug) associated with exposure Maxigesic® IV
|
During treatment period (≥ 48 hours - 5 days)
|
Incidence of TEAEs of Interest
Time Frame: During treatment period (≥ 48 hours - 5 days)
|
The incidence of TEAEs of interest (cardiovascular, gastrointestinal, renal, hepatic, administration site conditions and bleeding-related events)
|
During treatment period (≥ 48 hours - 5 days)
|
Changes in Blood Pressure
Time Frame: From the baseline (Day 1 prior to surgery) until 7 days after the last dose
|
Systolic and Diastolic Blood Pressured Measured every 24 hours
|
From the baseline (Day 1 prior to surgery) until 7 days after the last dose
|
Changes in Heart Rate
Time Frame: From the baseline (Day 1 prior to surgery) until 7 days after the last dose
|
Measured every 24 hours
|
From the baseline (Day 1 prior to surgery) until 7 days after the last dose
|
Changes in Temperature
Time Frame: From the baseline (Day 1 prior to surgery) until 7 days after the last dose
|
Measured every 24 hours
|
From the baseline (Day 1 prior to surgery) until 7 days after the last dose
|
Changes in Respiratory Rate
Time Frame: From the baseline (Day 1 prior to surgery) until 7 days after the last dose
|
Respiratory Rate Measured every 24 hours
|
From the baseline (Day 1 prior to surgery) until 7 days after the last dose
|
Changes in Hematology Values (Hemoglobin)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Hematology Values (Hematocrit)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Hematology Values (Platelet Count)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Hematology Values (Red Blood Cell Count)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Hematology Values (White Blood Cell Count)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Hematology Values (Differential Leukocyte Count)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Hematology test was Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Sodium)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Potassium)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Urea)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Creatinine)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Phosphate)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Glucose)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Albumin)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Total Protein)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Alkaline Phosphates)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Gamma-glutamyl Transferase)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Blood Biochemistry was Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Aspartate Transaminase)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Blood Chemistry (AST) was Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Alanine Transaminase)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Blood Chemistry (ALT) was Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Blood Biochemistry Values (Bilirubin)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
Measured at screening visit and at the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in ECG (Electrocardiography) Status (Normal/Abnormal)
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
All components of the ECG will be analysed to assess safety (P wave, QRS Complex, QT interval, PR interval, T wave, ST segment, U wave, PR segment) in 5 categories of the shift from baseline to the end of treatment from: Normal to Normal Normal to Abnormal NCS (Non-clinically Significant) Abnormal NCS to Normal Abnormal NCS to Abnormal NCS Missing |
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Changes in Hepatic Enzymes From Baseline to the End of the Treatment
Time Frame: Prior to surgery, on Day 1 and at discharge (Day 5)
|
The elevation in hepatic enzymes (ALP, ALT, AST, GGT) from baseline to the end of the treatment
|
Prior to surgery, on Day 1 and at discharge (Day 5)
|
Patient's Global Evaluation of the Study Drug
Time Frame: 5 days after the first dose
|
Summary of the patients' ratings of the study medication (1 = Poor; 2 = Fair; 3 = Good; 4 = Very Good; 5 = Excellent)
|
5 days after the first dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ira Gottlieb, DPM, Chesapeake Research Group
- Principal Investigator: Simon Carson, MD, Southern Clinical Trials Ltd
- Principal Investigator: Gregory L Ruff, MD, Chapel Hill Research Group
- Principal Investigator: Nigel Gilchrist, MD, CGM Research Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFT-MXIV-11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Pain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
VA Office of Research and DevelopmentRecruitingTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty (Postoperative Pain)United States
-
VA Office of Research and DevelopmentCompletedTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty(Postoperative Pain)United States
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
Clinical Trials on Maxigesic® IV
-
AFT Pharmaceuticals, Ltd.Completed
-
Ajou University School of MedicineNot yet recruitingOpioid UseKorea, Republic of
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingPostoperative HypothermiaFrance
-
Smiths Medical, ASD, Inc.CompletedPeripheral Intravenous CatheterCanada
-
AFT Pharmaceuticals, Ltd.Withdrawn
-
AFT Pharmaceuticals, Ltd.Completed
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdvanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | Stage A Adult Primary Liver Cancer (BCLC) | Stage B Adult Primary Liver Cancer (BCLC)United States
-
Lazarski UniversityPoznan University of Medical Sciences; Wroclaw Medical University; Medical University...CompletedShock | Emergency Medicine | Cardiopulmonary ArrestPoland
-
Foundation for Innovative New Diagnostics, SwitzerlandCompleted
-
National Taiwan University HospitalMinistry of Science and Technology, Taiwan; TeleflexCompletedVascular Access | Out-of-Hospital Cardiac Arrest | Intraosseous Access | Emergency Medical Service | Intravenous AccessTaiwan